drugset
drugset / Trial / NCT03672006

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006 ↗

Phase 2 Completed 20 enrolled Medical College of Wisconsin
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing the rate of clinically diagnosed central line associated blood stream infection (CLABSI) or venous thromboembolism (VTE) in central venous catheters (CVC) compared to standard of care heparin dwell.

Timeline

Start
2019-04-22
Primary completion
2019-12-15
Completion
2019-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.5 mg Other
Subject Alteplase Protein / enzyme biologic 1 mg Other
Subject Alteplase Protein / enzyme biologic 2 mg Other
Comparator Heparin Other / unclassified 0.5 ml Other
Comparator Heparin Other / unclassified 1 ml Other
Comparator Heparin Other / unclassified 2 ml Other

Indications

venous thromboembolism